Key result
Study protocol evaluates the incidence and impact of CAR T-cell therapy-associated cardiomyopathy in non-Hodgkin lymphoma.
Observational
Answers are grounded in this paper and cite their sources.
cardiotoxicity cytokine release syndrome heart failure lymphoma, non-Hodgkin receptors, chimeric antigen tisagenlecleucel A doptive cell therapy using chimeric antigen receptor (CAR) T cells augments the ability of the patient's immune system to recognize and destroy cancer cells. Genetically modified autologous T-cell agents that target CD-19, tisagenlecleucel and axicabtagene ciloleucel, are currently approved for the treatment of children with B-cell acute lymphocytic leukemia and adults with aggressive B-cell lymphoma. Cytokine release syndrome (CRS) is a frequent adverse effect of CAR T-cell therapy and has been associated with cardiotoxicity. In this study, we examined the incidence and impact of CAR T-cell therapy-associated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Ganatra et al. (2020) conducted an observational in Refractory or Relapsed Non-Hodgkin Lymphoma. Chimeric Antigen Receptor (CAR) T-cell therapy was evaluated on Incidence and impact of CAR T-cell therapy-associated cardiomyopathy. The abstract outlines a study to examine the incidence of CAR T-cell therapy-associated cardiomyopathy in patients with non-Hodgkin lymphoma, but reports no quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: